Improved penicillin susceptibility of Streptococcus pneumoniae and increased penicillin consumption in Japan, 2013-18.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2020
Historique:
received: 26 07 2020
accepted: 01 10 2020
entrez: 22 10 2020
pubmed: 23 10 2020
medline: 18 12 2020
Statut: epublish

Résumé

To examine the association between penicillin susceptibility of Streptococcus pneumoniae and penicillin consumption in Japan. We used Japan Nosocomial Infection Surveillance data on the susceptibility of S. pneumoniae and sales data obtained from IQVIA Services Japan K.K. for penicillin consumption. We analysed both sets of data by decomposing them into seasonality and chronological trend components. The cross-correlation function was checked using Spearman's rank correlation coefficient to examine the correlation between susceptibility and consumption. After adjusting for seasonality, the susceptibility of S. pneumoniae to penicillins gradually improved (55.7% in 2013 and 60.6% in 2018, respectively) and penicillin consumption increased during the same period (0.76 defined daily doses per 1,000 inhabitants per day [DID] in 2013, and 0.89 DID in 2018). The results showed positive cross-correlation (coefficient 0.801, p-value < 0.001). In contrast, cephalosporin consumption decreased (3.91 DID in 2013 and 3.19 DID in 2018) and showed negative cross-correlation with susceptibility of S. pneumoniae to penicillins (coefficient -0.981, p-value < 0.001). The rates of penicillin-susceptible S. pneumoniae isolates did not negatively correlate with penicillin consumption at the population level. Increased penicillin consumption might not impair the penicillin susceptibility of S. pneumoniae.

Identifiants

pubmed: 33091045
doi: 10.1371/journal.pone.0240655
pii: PONE-D-20-23245
pmc: PMC7580930
doi:

Substances chimiques

Anti-Bacterial Agents 0
Cephalosporins 0
Penicillins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0240655

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

J Antimicrob Chemother. 2020 Apr 1;75(Supplement_1):i88-i99
pubmed: 32337598
Clin Microbiol Infect. 2014 May;20 Suppl 5:45-51
pubmed: 24313448
J Antimicrob Chemother. 2016 May;71 Suppl 1:i103-9
pubmed: 27048578
BMC Health Serv Res. 2020 Feb 28;20(1):153
pubmed: 32111202
J Antimicrob Chemother. 2016 May;71 Suppl 1:i33-43
pubmed: 27048581
Lancet Glob Health. 2018 Jul;6(7):e744-e757
pubmed: 29903376
Sci Rep. 2020 Feb 26;10(1):3502
pubmed: 32103110
Curr Opin Crit Care. 2006 Oct;12(5):470-6
pubmed: 16943728
Antimicrob Agents Chemother. 1999 Feb;43(2):357-9
pubmed: 9925532
BMJ. 2010 May 18;340:c2096
pubmed: 20483949
J Antimicrob Chemother. 2016 Jun;71(6):1564-9
pubmed: 26892779
Expert Opin Pharmacother. 2008 Feb;9(2):229-41
pubmed: 18201146
J Infect Chemother. 2016 Jul;22(7 Suppl):S1-S65
pubmed: 27317161
J Antimicrob Chemother. 2016 May;71 Suppl 1:i93-102
pubmed: 27048586
J Antimicrob Chemother. 2018 Feb 1;73(suppl_2):ii36-ii43
pubmed: 29490058
BMC Health Serv Res. 2018 Oct 20;18(1):799
pubmed: 30342499
Clin Infect Dis. 2006 Jan 15;42(2):224-33
pubmed: 16355333
J Antimicrob Chemother. 2018 Jul 1;73(suppl_7):vii5-vii11
pubmed: 29982570
Antimicrob Agents Chemother. 2014 May;58(5):2763-6
pubmed: 24590486
Lancet. 2009 Sep 12;374(9693):893-902
pubmed: 19748398
Lancet Infect Dis. 2018 Jan;18(1):18-20
pubmed: 29303731
J Antimicrob Chemother. 2016 May;71 Suppl 1:i45-61
pubmed: 27048582
Clin Infect Dis. 2002 Jan 1;34(1):15-21
pubmed: 11731940
Lancet Glob Health. 2019 Jul;7(7):e861-e871
pubmed: 31200888
BMC Med. 2020 Apr 24;18(1):108
pubmed: 32326969
PLoS One. 2018 Nov 5;13(11):e0207017
pubmed: 30395640
J Antimicrob Chemother. 2002 Mar;49(3):433-6
pubmed: 11864942
J Antimicrob Chemother. 2016 May;71 Suppl 1:i63-9
pubmed: 27048583
J Infect Chemother. 2018 Jun;24(6):414-421
pubmed: 29428566
PLoS One. 2019 Oct 16;14(10):e0223835
pubmed: 31618258
J Antimicrob Chemother. 2018 Apr 1;73(suppl_5):v36-v42
pubmed: 29659884
BMC Health Serv Res. 2020 May 11;20(1):399
pubmed: 32393267
J Antimicrob Chemother. 2009 Aug;64(2):336-42
pubmed: 19520718
J Hosp Infect. 2019 Jun;102(2):226-233
pubmed: 30321629
J Antimicrob Chemother. 2016 May;71 Suppl 1:i3-19
pubmed: 27048580
J Antimicrob Chemother. 2018 Jun 1;73(6):1700-1707
pubmed: 29394363
J Antimicrob Chemother. 2016 May;71 Suppl 1:i21-31
pubmed: 27048579
PLoS One. 2019 Aug 15;14(8):e0221133
pubmed: 31415656
J Antimicrob Chemother. 2016 May;71 Suppl 1:i71-83
pubmed: 27048584
J Antimicrob Chemother. 2000 Oct;46(4):557-64
pubmed: 11020252

Auteurs

Shinya Tsuzuki (S)

AMR Clinical Reference Center, National Center for Global Health and Medicine, Tokyo, Japan.
Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.

Takayuki Akiyama (T)

AMR Clinical Reference Center, National Center for Global Health and Medicine, Tokyo, Japan.

Nobuaki Matsunaga (N)

AMR Clinical Reference Center, National Center for Global Health and Medicine, Tokyo, Japan.

Koji Yahara (K)

Antimicrobial Resistance Research Center, National Institute of Infectious Diseases, Tokyo, Japan.

Keigo Shibayama (K)

Antimicrobial Resistance Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
Department of Bacteriology II, National Institute of Infectious Diseases, Tokyo, Japan.

Motoyuki Sugai (M)

Antimicrobial Resistance Research Center, National Institute of Infectious Diseases, Tokyo, Japan.

Norio Ohmagari (N)

AMR Clinical Reference Center, National Center for Global Health and Medicine, Tokyo, Japan.
Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH